Epstein-Barr Virus-Positive Mucocutaneous Ulcer Mimicking Peri-Implantitis in a Patient With Systemic Lupus Erythematosus

Autor(es)

Takahama Jr, Ademar ; de Lima, Heliton Gustavo ^[1] ; Ito, Fabio Augusto ^[1] ; Ribeiro-Silva, Alfredo ^[2] ; Leon, Jorge Esquiche ^[3]

Afiliação do(s) autor(es)

^[1] Takahama Jr, Jr., Ademar, Univ Estadual Londrina, Dept Oral Med & Pediat Dent, Londrina - Brazil

^[2] Univ Sao Paulo, Dept Pathol & Forens Med, Ribeirao Preto Med Sch, Ribeirao Preto - Brazil

^[3] Univ Sao Paulo, Dept Stomatol Publ Oral Hlth & Forens Dent, Sch Dent Ribeirao Preto, Pathol, Ribeirao Preto - Brazil

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY; v. 77, n. 5, p. 977-984, MAY 2019.
• Citações Web of Science: 0

Resumo

Epstein-Barr virus-positive mucocutaneous ulcer (EBVMCU) is characterized by cutaneous and/or mucosal ulcers in patients receiving immunosuppressive medication or with age-related immunosenescence. Its microscopic appearance often leads to a diagnostic challenge, sometimes mimicking an overt lymphoma. A 47-year-old woman, with a previous diagnosis of systemic lupus erythematosus, was referred for evaluation of a gingival ulcer, present for about 2 months and located in the maxillary peri-implant mucosa around implants, resembling peri-implantitis. An incisional biopsy was performed, and the microscopic evaluation showed a polymorphic infiltrate with some Reed-Sternberg-like cells. Immunohistochemistry showed positive findings for CD20, CD30, CD45, PAX-5, MUM-1, LMP-1 and EBER1/2, establishing the diagnosis of EBVMCU. After 2 months, total regression of the lesion was noted without any intervention. We discuss the possible association between the EBVMCU and systemic lupus erythematosus; to our knowledge, this is the first report of an EBVMCU simulating peri-implantitis. (C) 2019 American Association of Oral and Maxillofacial Surgeons (AU)

• Processo FAPESP: 16/11419-0 - Correlação clinicopatológica do grau de diferenciação, expressão de tetraspaninas, agentes virais e proliferação celular em uma ampla série de carcinomas espinocelulares da região de cabeça e pescoço
• Beneficiário: Jorge Esquiche León
• Linha de fomento: Auxílio à Pesquisa - Regular
• Processo FAPESP: 16/02713-2 - Efeitos da terapia com erlotinib e gefitinib em associação ao ácido all-trans retinóico e trióxido de arsênico na leucemia promielocítica aguda: estudo in vitro, ex vivo e em modelo experimental murino
• Beneficiário: Luciana Yamamoto de Almeida
• Linha de fomento: Bolsas no Brasil - Pós-Doutorado